The interplay between metabolic reprogramming, mitochondrial impairment, and steroid response in proliferative vitreoretinopathy

被引：0
作者：
Huang, Xinyuan [1 ]
Li, Qingbo [1 ]
Xu, Manhong [1 ]
Sun, Shuo [1 ]
Gong, Yi [1 ]
Luan, Rong [1 ]
Wang, Manqiao [1 ]
Shao, Yan [1 ]
Li, Xiaorong [1 ]
机构：
[1] Tianjin Med Univ, Sch Optometry, Tianjin Branch,Natl Clin Res Ctr Ocular Dis,Eye Ho, Tianjin Key Lab Retinal Funct & Dis,Eye Inst & Sch, 251 Fu Kang Rd, Tianjin 300384, Peoples R China
来源：
FREE RADICAL BIOLOGY AND MEDICINE | 2025年 / 229卷
基金：
中国国家自然科学基金;
关键词：
Proliferative vitreoretinopathy; Metabolic reprogramming; Mitochondria; Retinal pigment epithelium; Steroid; RETINAL-DETACHMENT;
D O I：
10.1016/j.freeradbiomed.2025.01.033
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Proliferative vitreoretinopathy (PVR) is a major cause of rhegmatogenous retinal detachment repair failure. Despite many attempts to find therapeutics for PVR, no pharmacotherapy has been proven effective. Steroids, as the epitome, show uncertain clinical effectiveness, which lacks an explanation and hints at unappreciated mechanisms of PVR. In this study, we investigated the involvement of metabolic reprogramming, mitochondrial impairment, and their association with steroid effectiveness in PVR using dexamethasone (Dex) as an example. Proteomics of vitreous samples from PVR patients demonstrated an upregulation in the glycolysis pathway. Transcriptomics of PVR tissues (dataset GSE179603) revealed downregulations in oxidative phosphorylation (OXPHOS), mitochondrial respiration, and mitochondrial quality control-related pathways. Transcriptomics of TGF(3 and TNF alpha (TNT)-induced retinal pigment epithelial (RPE) cell model (GSE176513) confirmed the changes in glycolysis, OXPHOS, and mitochondria and also revealed downregulation of Dex response pathway with increased duration of TNT exposure. Transcriptomics of mouse RPE/choroid following Dex intravitreal injections (GSE49872) showed that glycolysis decreased at 1-week postinjection but increased at 1-month postinjection; OXPHOS increased but gradually decreased with treatment duration. The dispase-induced mouse PVR model revealed that a simultaneous Dex injection could alleviate PVR severity rather than an injection 5 days after the PVR induction. The TGF(32-induced RPE cell model demonstrated the enhancement of EMT, oxidative stress, and mitochondrial impairment, which could be alleviated by Dex: Cellular ROS were accumulated; the mRNA expressions of antioxidases (GPX, SOD1 and TXN2) were decreased; mitochondrial morphology and dynamics were impaired, exhibiting decreases in mitochondrial heterogeneity, mitochondrial length and MFN2 expression; Mitochondrial membrane potential showed an elevation; and mitophagy was decreased, related to reduced Parkin recruitment. These results demonstrate the essential roles of metabolic reprogramming and mitochondrial dysfunction in PVR pathology, which is associated with the therapeutic effect of steroids. Steroid intervention might benefit the treatment of PVR in the early rather than late stages.
引用
收藏
页码：485 / 498
页数：14
相关论文
共 43 条
  • [1] Wickham L., Ho-Yen G.O., Bunce C., Wong D., Charteris D.G., Surgical failure following primary retinal detachment surgery by vitrectomy: risk factors and functional outcomes, Br. J. Ophthalmol., 95, 9, pp. 1234-1238, (2011)
  • [2] Mudhar H.S., A brief review of the histopathology of proliferative vitreoretinopathy (PVR), Eye, 34, 2, pp. 246-250, (2020)
  • [3] Chaudhary R., Scott R.A.H., Wallace G., Berry M., Logan A., Blanch R.J., Inflammatory and fibrogenic factors in proliferative vitreoretinopathy development, Trans Vis Sci Tech, 9, 3, (2020)
  • [4] Chen Z., Shao Y., Li X., The roles of signaling pathways in epithelial-to-mesenchymal transition of PVR, Mol. Vis., 5, (2015)
  • [5] Zou H., Shan C., Ma L., Liu J., Yang N., Zhao J., Polarity and epithelial-mesenchymal transition of retinal pigment epithelial cells in proliferative vitreoretinopathy, PeerJ, 8, (2020)
  • [6] Charteris D.G., Proliferative vitreoretinopathy: revised concepts of pathogenesis and adjunctive treatment, Eye, 34, 2, pp. 241-245, (2020)
  • [7] Ferro D.L., Artemiev D., Zandi S., Zinkernagel M.S., Anguita R., Proliferative vitreoretinopathy: an update on the current and emerging treatment options, Graefes Arch. Clin. Exp. Ophthalmol., 262, 3, pp. 679-687, (2024)
  • [8] Bonfiglio V., Reibaldi M., Macchi I., Et al., Preoperative, intraoperative and postoperative corticosteroid use as an adjunctive treatment for rhegmatogenous retinal detachment, JCM, 9, 5, (2020)
  • [9] Banerjee P.J., Quartilho A., Bunce C., Et al., Slow-release dexamethasone in proliferative vitreoretinopathy, Ophthalmology, 124, 6, pp. 757-767, (2017)
  • [10] Koerner F., Koerner-Stiefbold U., Garweg J.G., Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial, Graefes Arch. Clin. Exp. Ophthalmol., 250, 7, pp. 981-987, (2012)
12345